Rani Therapeutics Holdings (RANI) Other Non-Current Liabilities (2020 - 2021)
Rani Therapeutics Holdings (RANI) posted Other Non-Current Liabilities of $606000.0 for Q2 2021, up 89.38% on a QoQ basis from $320000.0 in Q4 2020.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends
Rani Therapeutics Holdings has reported Other Non-Current Liabilities for 2 years, with the latest figure at $606000.0 in Q2 2021.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $606000.0 in Q2 2021; TTM through Jun 2021 was $606000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $320000.0, changed N/A from the prior year.
- Other Non-Current Liabilities was $606000.0 for Q2 2021 at Rani Therapeutics Holdings, up from $320000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $606000.0 in Q2 2021, with the low at $320000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - |